Trial Profile
A Retrospective study evaluating crizotinib efficacy and its relation with Bim deletion polymorphism in patients with ALK/ROS1 fusion-positive non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Oct 2018
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer
- 31 Mar 2017 New trial record
- 27 Mar 2017 Results published in the Cancer